4.6 Article

Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis

期刊

PLOS ONE
卷 16, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0245696

关键词

-

资金

  1. National Institutes of Health [R01HL122372]
  2. Cystic Fibrosis Foundation [ASHARE15A0]
  3. Cystic Fibrosis Foundation Research Development Program Grant [STANTO19R0]

向作者/读者索取更多资源

Data on adverse events in research bronchoscopy with BAL in CF patients is lacking. We investigated safety of bronchoscopy in adult CF patients, finding that CF subjects had similar adverse event profiles to healthy controls, but with higher rates of fevers, particularly in those with lower FEV1 values. Our data suggest that research bronchoscopy with BAL is safe in CF subjects, especially if limited to those with an FEV1 > 65% predicted.
Data on adverse events from research bronchoscopy with bronchoalveolar lavage (BAL) in patients with cystic fibrosis (CF) is lacking. As research bronchoscopy with BAL is useful for isolation of immune cells and investigation of CF lung microbiome, we sought to investigate the safety of bronchoscopy in adult patients with CF. Between November 2016 and September 2019, we performed research bronchoscopies on CF subjects (32) and control subjects (82). Control subjects were nonsmokers without respiratory disease. CF subjects had mild or moderate obstructive lung disease (FEV1 > 50% predicted) and no evidence of recent CF pulmonary exacerbation. There was no significant difference in the age or sex of each cohort. Neither group experienced life threatening adverse events. The number of adverse events was similar between CF and control subjects. The most common adverse events were sore throat and cough, which occurred at similar frequencies in control and CF subjects. Fever and headache occurred more frequently in CF subjects. However, the majority of fevers were seen in CF subjects with FEV1 values below 65% predicted. We found that CF subjects had similar adverse event profiles following research bronchoscopy compared to healthy subjects. While CF subjects had a higher rate of fevers, this adverse event occurred with greater frequency in CF subjects with lower FEV1. Our data demonstrate that research bronchoscopy with BAL is safe in CF subjects and that safety profile is improved if bronchoscopies are limited to subjects with an FEV1 > 65% predicted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据